Related Experiment Video
Updated: May 27, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Study on the effects and mechanism of RRM2 on three gynecological malignancies
Luhan Yang1, Hongping Zhang2, Junfeng Wang3
1School of Medicine, Yunnan University, Kunming, Yunnan 650091, China.
Abstract:
Cervical cancer, endometrial cancer, and ovarian cancer are the three most common gynecological malignancies. Their occurrence seriously affects women's health and life. Despite aggressive treatments, some patients still find it difficult to benefit from available therapies. Ribonucleic acid reductase subunit M2 (RRM2) is a limiting RNR enzyme involved in DNA synthesis and damage repair and plays a crucial role in many key cellular processes such as cell proliferation, migration, invasion, and senescence. Many studies have also shown that RRM2 also has a significant impact on tumor progression. However, the role of RRM2 in gynecological tumors has not been systematically studied. Our bioinformatics analysis of datasets related to cervical, endometrial, and ovarian cancers revealed that RRM2 is a significantly differentially expressed gene common to these cancers. We found that RRM2 was significantly overexpressed in cervical, endometrial, and ovarian cancer tissues and cells, exhibiting overall pro-oncogenic effects. RRM2 promoted cell proliferation, migration invasion, angiogenesis, and cell cycle in gynecological tumors while inhibiting apoptosis. The potential oncogenic effects of RRM2 in gynecologic tumor cell lines were further demonstrated using the RRM2 inhibitor Triapine (3-AP). These pro-tumorigenic effects may then be mediated through the involvement of RRM2 in the p53 and Akt/mTOR signaling pathways, altering the expression of p53 and Akt/mTOR. Thus, RRM2 is potentially a candidate gene for the unified diagnosis of cervical, endometrial, and ovarian cancers.
Insights
Ribonucleic acid reductase subunit M2 (RRM2) is overexpressed in cervical, endometrial, and ovarian cancers. This gene promotes tumor growth and may serve as a unified diagnostic marker for these gynecological malignancies.
Area of Science:
- Gynecologic Oncology
- Molecular Biology
- Bioinformatics
Background:
- Cervical, endometrial, and ovarian cancers are leading gynecological malignancies with challenging treatment outcomes.
- Ribonucleic acid reductase subunit M2 (RRM2) is vital for DNA synthesis and repair, implicated in tumor progression.
- The specific role of RRM2 in gynecological tumors requires systematic investigation.
Purpose of the Study:
- To investigate the expression and function of RRM2 in cervical, endometrial, and ovarian cancers.
- To determine if RRM2 serves as a common molecular marker across these gynecological malignancies.
- To elucidate the underlying signaling pathways influenced by RRM2 in gynecological tumor progression.
Main Methods:
- Bioinformatic analysis of gene expression datasets for cervical, endometrial, and ovarian cancers.
- In vitro experiments using gynecological tumor cell lines to assess RRM2 function.
- Treatment with the RRM2 inhibitor Triapine (3-AP) to evaluate its effects on tumor cells.
- Analysis of RRM2's impact on key cellular processes including proliferation, migration, invasion, apoptosis, and cell cycle progression.
- Investigation of RRM2's interaction with p53 and Akt/mTOR signaling pathways.
Main Results:
- RRM2 was identified as a significantly differentially expressed gene across cervical, endometrial, and ovarian cancers.
- RRM2 exhibited significant overexpression in tumor tissues and cells, indicating a pro-oncogenic role.
- RRM2 promoted proliferation, migration, invasion, angiogenesis, and cell cycle progression while inhibiting apoptosis in gynecological tumors.
- The RRM2 inhibitor Triapine (3-AP) demonstrated potential in mitigating RRM2's oncogenic effects.
- RRM2's pro-tumorigenic effects are potentially mediated through modulation of the p53 and Akt/mTOR signaling pathways.
Conclusions:
- RRM2 is a commonly overexpressed oncogene in cervical, endometrial, and ovarian cancers.
- RRM2 plays a significant role in promoting tumor progression through various cellular mechanisms.
- RRM2 inhibition presents a potential therapeutic strategy for these gynecological malignancies.
- RRM2 may serve as a promising candidate for the unified diagnosis and targeted therapy of cervical, endometrial, and ovarian cancers.
Related Concept Videos
01:22MicroRNAs
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
02:23Abnormal Proliferation
02:38Mitogens and the Cell Cycle
01:24Disorders of the Female Reproductive System
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...